Navigation Links
Endu Receives Gold Medal for Outstanding Chinese Patented Invention Award
Date:3/3/2008

NANJING, CHINA, March 4 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, announced today that the company is a gold medal winner of the 10th Outstanding Chinese Patented Invention Award bestowed by the State Intellectual Property Office of the People's Republic of China (SIPO).

The award, established by SIPO in 1989, is the exclusive government patent award held every two years to encourage technology innovation and to boost intellectual property protection, and has been approved by the World Intellectual Property Organization (WIPO).

SIPO received 318 applicants for the 10th Outstanding Chinese Patented Invention Award from all over the country recommended by the ministries, local IP administrations, nation-level enterprises, the Chinese Academy of Sciences and the members of Chinese Academy of Engineering. Fifteen outstanding Chinese patent invention gold medal winners were selected after several rounds of strict examination.

The award is for the methodology pioneered by Simcere to produce Endu, a modified version of endostatin, which has brought tremendous social benefit to thousands of patients across China. Endu has been engineered to contain an additional nine-amino acid sequence to enhance protein purification, solubility and stability and has been shown to improve the function of endostatin, which is a genetically engineered protein that interferes with the growth of blood vessels to a tumor, thereby starving and preventing the growth of tumor cells.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stoke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Highlands Acquisition Corp. Receives Non-Compliance Letter From Amex
2. Vapotherm CEO Receives Top Business Leadership Award From World Trade Center Institute
3. Fujifilm Receives FDA Approval for Unity SpeedSuite(TM)
4. Bart De Strooper receives prestigious $200,000 Alzheimer Prize
5. The Female Health Company Receives USAID DELIVER PROJECT Order for 6.1 Million Units
6. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
7. Boca Pharmacal Receives FDA Approval for Carbinoxamine Oral Solution
8. IDC receives patent on dual energy imaging technology
9. Kryptiq Customer Receives HIMSS Nicholas E. Davies Award of Excellence
10. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
11. Healthy Start of Southwest Florida Receives Grant From March of Dimes to Assess Needs of Pregnant Women and Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is on ... security. Most importantly, employees are the single most important asset in creating value ... unhappy? , Just under half of American workers are emotionally checked out with ...
(Date:4/29/2016)... ... , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite ... a light breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers ... and 1-mile walk were held to increase awareness about Lyme disease and to ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Switzerland , April 27, 2016 ... AG announced the launch of a Phase 2 clinical ... residual hearing in patients undergoing cochlear implantation (CI) surgery. ... recruiting patients in Germany and ... into the middle ear at the time of surgery. ...
(Date:4/26/2016)... 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... at the Deutsche Bank 41 st Annual Health Care ... You are invited to listen to the live ... access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay ... of the live event and accessible at the links above ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology: